Editorial note: this article summarises published research on BPC-157 and TB-500. Baclabs does not sell BPC-157, TB-500 or any peptide; we supply bacteriostatic water and reconstitution consumables. Nothing here is medical advice.
The “Wolverine stack” is forum shorthand for BPC-157 + TB500 used together, on the theory that two peptides with different repair mechanisms should heal soft tissue faster than either alone. Some vendors sell the pair pre-blended in one vial under names such as “HEAL (BPC-157 + TB500)”. The idea is intuitive. The evidence for it is a single 2026 rat study, and that study found no additive benefit.
This article compares the two compounds, explains why the synergy argument is plausible on paper, sets out what the combination study actually showed, and works through the mix-ratio and reconstitution arithmetic for people handling the vials. It sits under the regenerative peptides hub, which covers the wider evidence and regulatory picture.
TB 500 vs BPC 157: two different molecules
BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) modelled on a protein in human gastric juice. In rat models from Predrag Sikirić’s Zagreb group it accelerated healing of transected Achilles tendon, tendon-to-bone detachment, crushed muscle and ligament, typically at 10 µg/kg or 10 ng/kg intraperitoneally once daily [1][2]. The proposed mechanisms are vascular: upregulation of VEGFR2 and activation of the VEGFR2-Akt-eNOS pathway, interaction with the nitric oxide system, and early induction of the growth-response gene egr-1 [1].
TB-500 is usually the acetylated heptapeptide Ac-LKKTETQ, residues 17–23 of thymosin beta-4 (Tβ4) plus one extra residue. Tβ4 is the major G-actin sequestering protein in mammalian cells, and this segment is its actin-binding domain, which in cell and animal studies promotes endothelial migration, angiogenesis and wound closure [3][4]. The human trials of Tβ4 (RegeneRx’s RGN-137 gel and RGN-259 eye drops) used the full 43-residue protein topically, not the fragment [5].
| BPC-157 | TB-500 | |
|---|---|---|
| Length | 15 residues | 7 residues (fragment of 43-residue Tβ4) |
| Proposed mechanism | Angiogenesis via VEGFR2/NO signalling; cytoprotection | Actin binding; cell migration; angiogenesis |
| Animal evidence | Extensive rat literature, mostly one group | Moderate; mostly full-length Tβ4 |
| Human evidence | Two-person IV pilot; retrospective knee series; no RCT [6][7] | None for the fragment; phase 2–3 topical/ocular trials of full Tβ4 [5] |
| Half-life (animal) | Under 30 minutes in rats and dogs [8] | Not established in published pharmacokinetic studies |
| WADA | Prohibited, S0 [9] | Prohibited, S2 (“thymosin-β4 and its derivatives, e.g. TB-500”) [9] |
Why BPC-157 + TB500 is stacked
The case for BPC-157 + TB500 rests on complementary mechanisms. Repair needs both a blood supply and cells that can move into the wound; BPC-157’s reported effects are mostly vascular, TB-500’s are cytoskeletal. A two-hit model is easy to build. It was not tested in a controlled experiment until 2026: every earlier BPC-157 paper studied BPC-157 alone, and every Tβ4 paper studied Tβ4 alone. The stack was assembled by users, not researchers.
The one study that tested the combination
In 2026, Biçer and colleagues published a rat Achilles tendon repair model in Joint Diseases and Related Surgery [10]. Thirty-two male Sprague-Dawley rats were divided into four groups of eight: vehicle control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and both together, all given intraperitoneally for 30 days after surgical repair. The findings:
- TB-500 alone produced significantly higher maximum load to failure than control (p < 0.05), lower Bonar and Movin histology scores and better collagen alignment.
- BPC-157 alone produced numerically higher biomechanical values that did not reach statistical significance, and improvements in some histological parameters without a significant change in total score.
- The combination “did not confer additional benefits compared to either agent alone”.
The authors called the results preliminary and asked for larger studies with longer follow-up. Eight rats per group is small and four weeks is early in tendon remodelling. But the study is the only direct test of the Wolverine stack in the peer-reviewed literature, and its answer was that stacking added nothing. It also found TB-500 outperforming BPC-157, the reverse of the usual forum hierarchy.
BPC 157 TB 500 mix ratio: what the numbers mean
Blended “HEAL” vials are commonly labelled with equal masses (for example 5 mg + 5 mg or 10 mg + 10 mg). That 1:1 ratio is a manufacturing convenience, not a literature-derived figure. The one combination study used 10 µg/kg BPC-157 against 60 µg/kg TB-500, a 1:6 mass ratio, and rodent-to-human scaling is not straightforward for peptides with different half-lives [8][10]. There is no published dose-finding work on the pair in any species.
Doses reported in the literature for each component, for context only:
- BPC-157 rodent studies: 10 µg/kg or 10 ng/kg daily, intraperitoneal or oral in drinking water at 0.16 µg/mL [1]. The 2022 pharmacokinetic paper mentions a proposed clinical dose of 200 µg per person per day, which has not been tested in a published efficacy trial [8].
- TB-500 rodent study: 60 µg/kg/day intraperitoneal [10]. Human Tβ4 trials used topical 0.01–0.1% gel or 0.1% eye drops, which do not translate to a systemic dose [5].
Vendor “protocols” of several hundred micrograms of each per day, or TB-500 loading phases of several milligrams a week, have no published source.
Reconstitution maths for a blended or separate vial
Whether the peptides come in one vial or two, the arithmetic is the same: concentration = mass ÷ diluent volume, and each unit on a U-100 insulin syringe is 0.01 mL.
| Vial | Bacteriostatic water | Concentration | Per U-100 unit |
|---|---|---|---|
| BPC-157 5 mg | 2 mL | 2,500 mcg/mL | 25 mcg |
| TB-500 5 mg | 2 mL | 2,500 mcg/mL | 25 mcg |
| Blend 5 mg + 5 mg (10 mg total) | 2 mL | 5,000 mcg/mL total; 2,500 mcg/mL of each | 25 mcg of each |
| Blend 10 mg + 10 mg (20 mg total) | 2 mL | 10,000 mcg/mL total; 5,000 mcg/mL of each | 50 mcg of each |
A blended vial locks the ratio: you cannot draw more of one peptide than the other. Separate vials let you set any ratio but double the reconstitution and the number of punctures. Both are multi-dose vials, so the diluent needs a preservative; plain sterile water has none, as explained in bacteriostatic vs sterile water. Baclabs supplies UK-stocked bacteriostatic water in 30 mL vials; the reconstitution guide covers technique, and storage and shelf life explains the 28-day rule after first puncture. Full worked examples for BPC-157 are in the BPC-157 protocol guide.
Regulatory and safety position
Neither peptide is a licensed medicine anywhere. In the US, both were placed in Category 2 of the FDA’s 503A bulk substances list in September 2023, the category for substances raising significant safety risks [11]. In July 2026 an FDA advisory committee voted 8–6 (one abstention) to recommend allowing compounding of BPC-157 and TB-500, against the opposition of FDA scientists; the vote is non-binding and no rule has changed [12]. In the UK, supplying either as a medicine breaches regulation 46 of the Human Medicines Regulations 2012, and the MHRA has said it disregards “research use” labels used to evade that [13][14]. Both are prohibited in sport [9].
Reported adverse effects in the animal literature are minimal, but no controlled human safety data exist for either compound by injection. The FDA’s stated concern is immunogenicity, particularly with impure product and parenteral routes [15]. Stacking two unstudied compounds does not reduce that uncertainty; it doubles it.
Frequently asked questions
Does the BPC-157 and TB-500 Wolverine stack work?
There is no human evidence either way. The only controlled test, a 2026 rat Achilles tendon study, found TB-500 alone improved tendon strength and histology, BPC-157 alone produced non-significant improvements, and the combination gave no additional benefit over either peptide on its own. The stack was built on mechanism, not on data.
What is the correct BPC 157 TB 500 mix ratio?
No ratio has been established. Pre-blended “HEAL” vials usually contain equal masses of each peptide, which reflects manufacturing convenience. The single rat combination study used 10 µg/kg BPC-157 with 60 µg/kg TB-500, a 1:6 ratio, and found no synergy at that ratio. Any ratio you see quoted online is an unsupported extrapolation.
TB 500 vs BPC 157: which has better evidence?
BPC-157 has far more animal papers, almost all from one group, and effectively no controlled human trials. Full-length thymosin beta-4 has phase 2 and 3 human trials as a topical gel and eye drop, but the TB-500 fragment itself has none. In the head-to-head rat tendon study, TB-500 performed better than BPC-157.
Can BPC-157 and TB-500 be mixed in the same vial?
Vendors sell them pre-blended, and both are reconstituted with the same diluent, so physical mixing is possible. Reconstituting two peptides in one vial fixes their ratio and means any degradation or contamination affects both. There are no published stability data for the mixture.
Is the Wolverine stack legal in the UK?
Buying for personal use is not an offence. Selling or supplying either peptide as a medicine without a marketing authorisation breaches the Human Medicines Regulations 2012, and the MHRA has said that “for research purposes” labelling does not change that where the product is clearly intended for human use. Neither peptide is prescribable as a licensed product.
References
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Seiwerth S, Sikiric P et al., Frontiers in Pharmacology, 2021
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 2003 (PMID 14554208)
- Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 2005 (PMID 16099219)
- Biological activities of thymosin beta4 defined by active sites in short peptide sequences. 2010 (PMID 20179146)
- RegeneRx Reports Phase II Venous Stasis Trial Results. Fierce Biotech, 2009
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. 2025 (PMID 40131143)
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. 2021 (PMID 34324435)
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. He L et al., Frontiers in Pharmacology, 2022
- The Prohibited List. World Anti-Doping Agency, 2026
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Biçer et al., Joint Diseases and Related Surgery, 2026 (PMID 42542926)
- 503A Bulk Drug Substances Categories Update, September 29 2023. Alliance for Pharmacy Compounding, 2023
- FDA Panel Backs 6 Peptides for Compounding. AJMC, July 2026
- The Human Medicines Regulations 2012, Regulation 46. legislation.gov.uk
- Grey-market peptides: what pharmacists need to know. The Pharmacist, April 2026
- FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting: BPC-157. US FDA, July 2026
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Bacteriostatic water is supplied for reconstitution of substances intended for research and for use as directed by a healthcare professional. Peptides and medicines discussed here may be unlicensed in the UK or prescription-only; consult a qualified clinician before using any medicine. Baclabs does not sell peptides.